Sichuan Biokin Pharmaceutical (SHA:688506) received approval from China's National Medical Products Administration for the clinical trials of combination therapies with the drug, BL-M14D1 (DLL3ADC), according to a Shanghai bourse filing on Monday.
The regulator allows the drug to be tested with PD-L1 monoclonal antibodies, anti-angiogenic agents and chemotherapy for the treatment of small cell lung cancer.
The drugmaker's shares rose 2% during the morning trade Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.